Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02280252 · ClinicalTrials.gov registry record · Phase 2
Study of Concurrent Paclitaxel and Radiation: Correlation of Tumor Profiles With Pathologic Response
A Phase 2 study of Breast Cancer, sponsored by NYU Langone Health.
- Completed
- Registry status
- Phase 2
- Development phase
- 69
- Enrollment target
- 1
- Study location
NCT02280252 is a Phase 2 study of Breast Cancer that has completed, run by NYU Langone Health. The registered enrollment target is 69 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02280252, a Phase 2 study of Breast Cancer, has completed, sponsored by NYU Langone Health.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 69 participants
- Enrollment target
- 1
- Study location
Study Summary
The need to understand LABC is especially compelling in populations and countries with limited resources, where breast cancer incidence is relatively low, but mortality is comparably high. In these settings access to appropriate cancer care is characteristically limited or often plainly nonexistent. In contrast to economically developed nations, where on average fewer than 20% of women present with breast cancer at advanced stages, LABC and metastatic disease are the most common stages at presentation in 50% or more women in Latin America, Asia and Africa.
Conditions Studied
Interventions
- DRUG Paclitaxel
- RADIATION Radiation therapy
Study Locations (1)
New York
- NYU Langone Medical Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 69 participants |
| Start Date | 2005-03 |
| Est. Completion | 2018-12-20 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02280252
The ClinicalTrials.gov registry entry for NCT02280252 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 69 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (98% lower). The listed sponsor is NYU Langone Health, which has 1,164 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 2 interventions - of which Paclitaxel is the first listed.
NCT02280252 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT02280252 about?
NCT02280252 is a clinical study titled "Study of Concurrent Paclitaxel and Radiation: Correlation of Tumor Profiles With Pathologic Response". The need to understand LABC is especially compelling in populations and countries with limited resources, where breast cancer incidence is relatively low, but mortality is comparably high. In these settings access to appropriate cancer care is characteristically limited or often plainly nonexistent....
What is the current status of trial NCT02280252?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 69 participants. The study started on 2005-03. Estimated completion is 2018-12-20.
What conditions does trial NCT02280252 study?
This clinical trial studies the following conditions: Breast Cancer.
What interventions are being tested in trial NCT02280252?
The interventions under investigation include: Paclitaxel (DRUG), Radiation therapy (RADIATION).
Who is sponsoring clinical trial NCT02280252?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02280252 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBC
RECRUITING · Phase 2
-
The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer
RECRUITING · Phase 2
-
Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC
RECRUITING · Phase 2
-
Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial
RECRUITING · Phase 2
-
Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score
RECRUITING · Phase 2
-
Precision Medicine in Action: Phase II Trial of Response Adaptive Ablative Pre-operative SPBI (RAPS) and Non-operative Sentinel Lymph Node Biopsy in Patients With Early-stage ER+ Breast Cancer: RAPS Trial
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.